Red Propolis Supplementation as a Strategy in Chronic Kidney Disease

Universidade Federal Fluminense

Status: Enrolling

Conditions: Chronic Kidney Disease; Inflammation; Oxidative Stress; Kidney Disease

Treatments: Dietary Supplement: Red Propolis; Other: Placebo Control

Study type: Interventional

Funder types: Other

Identifiers

NCT07597005

DeniseMafra23

Details and patient eligibility

About

The objective of this study is to evaluate the effects of red propolis on inflammation and oxidative stress in patients with chronic kidney disease on conservative management.

Full description

Chronic kidney disease (CKD) is associated with chronic systemic inflammation and oxidative stress, which contribute to disease progression and adverse outcomes. Red propolis is a natural substance rich in bioactive compounds with potential anti-inflammatory and antioxidant effects. Clinical evidence on its use in CKD patients is limited, and no studies have evaluated its impact on gene expression related to inflammation and oxidative stress. This randomized, double-blind, placebo-controlled trial will assess the effects of alcoholic extract of red propolis (200 mg/day for 8 weeks) on inflammatory and oxidative stress markers in patients with CKD stages 3-5 under conservative management. Blood samples will be collected at baseline and after intervention to evaluate routine biochemical parameters, inflammatory and oxidative stress markers, and gene expression. Nutritional status and dietary intake will also be assessed.

Enrollment: 40 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients with CKD stages 3-5 under conservative management

Exclusion criteria

• pregnant,
• lactating,
• smoker
• patients using antibiotics and antioxidant supplements in the last three months
• patients with autoimmune and infectious diseases,
• patients with cancer, liver disease, and AIDS

Trial design

Primary purpose: Health Services Research

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

40 participants in 2 patient groups, including a placebo group

Red Propolis Group

Experimental group

Description:

Patients with chronic kidney disease will receive capsules containing 200mg of red propolis / day for two months.

Treatment:

Dietary Supplement: Red Propolis

Placebo Group

Placebo Comparator group

Description:

Patients with chronic kidney disease will receive capsules containing 200mg of placebo/ day for two months.

Treatment:

Other: Placebo Control